PharmaTelevision®, the authoritative channel for the pharmaceutical, biotechnology and related industries, today announced that it is teaming up with the EBD Group to offer delegates at BIO-Europe a Television Interview and Media Training.
A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge
Oxford, UK, October 21 2010: In the current BioPharma economic climate; with smaller companies desperately needing the right development partners for survival and larger ones needing to support their existing businesses through making the right deals, having the best, most comprehensive, intelligence and insights are absolutely essential for success.
PharmaVentures gears up to shape pharmaceutical deals in Asia Pacific
Increasing demand for its services in the Asia-Pacific region has led PharmaVentures, a leading provider of specialist consultancy, advisory and intelligence services, to appoint Dr Robert Daniels as its dedicated Vice President for the region. Robert will be based in Sydney, Australia.
PharmaVentures helps secure investor for former MSD research site
Oxford, UK, January 19th, 2012 - PharmaVentures announced today that it was delighted to act as transaction advisor to MSD (operating in the US and Canada as Merck & Co) to secure its deal with BioCity Scotland, a new joint venture between BioCity Nottingham and Roslin BioCentre, for the former MSD research facility in Newhouse, Lanarkshire.
PharmaVentures Client QRx Pharma Announces Strategic Partnership with Actavis
Agreement for US sales of MoxDuo® IR to address the $2.5 billion acute pain market in 2012
Sydney, Australia and Bedminster, New Jersey – QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution of a binding Letter of Intent (LOI) with Actavis Inc. for the formation of a strategic partnership to commercialise MoxDuo IR in the US acute pain marketplace.
PharmaVentures Client Vital Foods Announces Partnership with Nestle Health Science
Mon 18 Jul 2011 : Vital Foods partners with Nestlé Health Science
Vital Foods today announced that Nestlé Health Science has become a strategic investor and taken a minority stake in the company. The terms of the transaction are not being disclosed.
PharmaVenture Client Bergen Bio Licenses R428
PharmaVentures Client BergenBio entered into an agreement for Rigel's preclinical candidate, R428 (now referred to as BGB324), an Axl kinase inhibitor for oncology.
PharmaVentures facilitates manufacturing divestment for UCB to Aesica Pharmaceuticals
Oxford, UK. 01 March 2011 - PharmaVentures Ltd acted as exclusive advisor and broker to the global biopharma company, UCB in its successful strategic partnership with UK-based developer and manufacturer Aesica Pharmaceuticals.
PharmaVentures acts as advisor and broker to Dr Reddy’s to identify and secure product marketing opportunities for the Russian/CIS market.
Oxford, UK, 26th October, 2010: PharmaVentures Ltd announced today that it had acted as the advisor and broker to the Indian pharmaceutical company Dr Reddy’s Laboratories in its successful marketing and distribution agreement with the UK healthcare company Vitabiotics Ltd for a range of nutraceutical products. The agreement provides Dr Reddy’s exclusive marketing rights in the Russian/CIS markets for two of Vitabiotics’ leading products - Jointace and Dietrim. Vitabiotics will supply these products on a long-term basis from its facilities in Europe.
PharmaVentures acts as exclusive advisor to sanofi-aventis in landmark divestment deal with Covance
Oxford, UK. 01 October 2010 - PharmaVentures are pleased to announce that they acted as transaction advisors and sale process executioners for sanofi-aventis in their strategic deal with Covance. Under the terms of the agreement, sanofi-aventis will retain access to some of the capabilities which have been divested to Covance as part of a long-term strategic alliance. Covance will provide sanofi-aventis with a 10-year sole source relationship for central lab services.
